Cargando…

Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report

Personal neoantigen vaccines are considered to be effective methods for inducing, amplifying and diversifying antitumor T cell responses. We recently conducted a clinical study that combined neoantigen nanovaccine with anti-PD-1 antibody. Here, we reported a case with a clear beneficial outcome from...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Jie, Liu, Qin, Shen, Jie, Qian, Xiaoping, Yan, Jing, Zhu, Yahui, Qiu, Xin, Lu, Changchang, Cen, Lanqi, Tian, Manman, Du, Juan, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901600/
https://www.ncbi.nlm.nih.gov/pubmed/35273594
http://dx.doi.org/10.3389/fimmu.2022.799026
_version_ 1784664400126279680
author Shao, Jie
Liu, Qin
Shen, Jie
Qian, Xiaoping
Yan, Jing
Zhu, Yahui
Qiu, Xin
Lu, Changchang
Cen, Lanqi
Tian, Manman
Du, Juan
Liu, Baorui
author_facet Shao, Jie
Liu, Qin
Shen, Jie
Qian, Xiaoping
Yan, Jing
Zhu, Yahui
Qiu, Xin
Lu, Changchang
Cen, Lanqi
Tian, Manman
Du, Juan
Liu, Baorui
author_sort Shao, Jie
collection PubMed
description Personal neoantigen vaccines are considered to be effective methods for inducing, amplifying and diversifying antitumor T cell responses. We recently conducted a clinical study that combined neoantigen nanovaccine with anti-PD-1 antibody. Here, we reported a case with a clear beneficial outcome from this treatment. We established a process that includes comprehensive identification of individual mutations, computational prediction of new epitopes, and design and manufacture of unique nanovaccines for this patient. Nanovaccine started after a relapse in third-line treatment. We assessed the patient’s clinical outcome and circulating immune response. In this advanced pancreatic cancer patient, the OS associated with the vaccine treatment was 10.5 months. A peptide-specific T-cell response against 9 of the 12 vaccine peptides could be detected sequentially. Robust neoantigen-specific T cell responses were also detected by IFN-γ ELISPOT and intracellular cytokine staining. In conclusion, sustained functional neoantigen-specific T cell therapy combined with immune checkpoint targeting may be well suited to help control progressive metastatic pancreatic cancer.
format Online
Article
Text
id pubmed-8901600
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89016002022-03-09 Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report Shao, Jie Liu, Qin Shen, Jie Qian, Xiaoping Yan, Jing Zhu, Yahui Qiu, Xin Lu, Changchang Cen, Lanqi Tian, Manman Du, Juan Liu, Baorui Front Immunol Immunology Personal neoantigen vaccines are considered to be effective methods for inducing, amplifying and diversifying antitumor T cell responses. We recently conducted a clinical study that combined neoantigen nanovaccine with anti-PD-1 antibody. Here, we reported a case with a clear beneficial outcome from this treatment. We established a process that includes comprehensive identification of individual mutations, computational prediction of new epitopes, and design and manufacture of unique nanovaccines for this patient. Nanovaccine started after a relapse in third-line treatment. We assessed the patient’s clinical outcome and circulating immune response. In this advanced pancreatic cancer patient, the OS associated with the vaccine treatment was 10.5 months. A peptide-specific T-cell response against 9 of the 12 vaccine peptides could be detected sequentially. Robust neoantigen-specific T cell responses were also detected by IFN-γ ELISPOT and intracellular cytokine staining. In conclusion, sustained functional neoantigen-specific T cell therapy combined with immune checkpoint targeting may be well suited to help control progressive metastatic pancreatic cancer. Frontiers Media S.A. 2022-02-22 /pmc/articles/PMC8901600/ /pubmed/35273594 http://dx.doi.org/10.3389/fimmu.2022.799026 Text en Copyright © 2022 Shao, Liu, Shen, Qian, Yan, Zhu, Qiu, Lu, Cen, Tian, Du and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Shao, Jie
Liu, Qin
Shen, Jie
Qian, Xiaoping
Yan, Jing
Zhu, Yahui
Qiu, Xin
Lu, Changchang
Cen, Lanqi
Tian, Manman
Du, Juan
Liu, Baorui
Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
title Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
title_full Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
title_fullStr Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
title_full_unstemmed Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
title_short Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
title_sort advanced pancreatic cancer patient benefit from personalized neoantigen nanovaccine based immunotherapy: a case report
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901600/
https://www.ncbi.nlm.nih.gov/pubmed/35273594
http://dx.doi.org/10.3389/fimmu.2022.799026
work_keys_str_mv AT shaojie advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT liuqin advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT shenjie advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT qianxiaoping advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT yanjing advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT zhuyahui advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT qiuxin advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT luchangchang advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT cenlanqi advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT tianmanman advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT dujuan advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport
AT liubaorui advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport